{"id":542609,"date":"2021-05-10T23:06:02","date_gmt":"2021-05-10T23:06:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542609"},"modified":"2021-05-10T23:06:02","modified_gmt":"2021-05-10T23:06:02","slug":"advanced-renal-cell-carcinoma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/advanced-renal-cell-carcinoma-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542609.html","title":{"rendered":"Advanced Renal Cell Carcinoma Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"Advanced<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Advanced Renal Cell Carcinoma (RCC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Advanced Renal Cell Carcinoma (RCC) , historical and forecasted epidemiology as well as the Advanced Renal Cell Carcinoma (RCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on ” Advanced Renal Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/p>\n

DelveInsight’s<\/span> “ Advanced Renal Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″<\/span> report delivers an in-depth understanding of the  Advanced Renal Cell Carcinoma, historical and forecasted epidemiology as well as the  Advanced Renal Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    A study stated that in the United States, the estimated number of diagnosed cases in 2018 is 65,340 and the estimated number of deaths is 14,970. The overall RCC incidence during the study period was 11.281 per 100,000 person-year. <\/span><\/p>\n<\/li>\n

  2. \n

    A study, wherein approximately 65% of patients with newly diagnosed RCC have localized disease at the time of diagnosis, while 25 to 30% have the advanced or metastatic disease; approximately 20 to 40% of patients with localized RCC will progress to metastatic RCC (mRCC). <\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.  Advanced Renal Cell Carcinoma market report covers a descriptive overview and comprehensive insight of the  Advanced Renal Cell Carcinoma Epidemiology and  Advanced Renal Cell Carcinoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2.  Advanced Renal Cell Carcinoma market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3.  Advanced Renal Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span><\/p>\n

    4. The  Advanced Renal Cell Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the  Advanced Renal Cell Carcinoma market.<\/span><\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/advanced-renal-cell-carcinoma-rcc-market<\/span><\/a><\/strong><\/p>\n

    Advanced Renal Cell Carcinoma: Overview<\/strong><\/p>\n

    Renal Cell Carcinoma (RCC), also known as kidney cancer, hypernephroma or renal adenocarcinoma or the Grawitz tumor, is the most common type of kidney cancer, accounting for 85% of primary renal malignancies in adults. It is a disease in which malignant (cancer) cells are found in the lining of tubules in the kidney. RCC is a fast-growing cancer and often spreads to the lungs and surrounding organs. It varies from Stage I with tumor confined to kidney tissues to Stage IV with tumor spread to different organs. The stage IV condition of the tumor leads to the metastatic or advanced stage of renal cell carcinoma. <\/span><\/p>\n

    The key player involved in the Advanced Renal Cell Carcinoma market:<\/strong><\/a><\/p>\n

      \n
    1. \n

       Nektar Therapeutics <\/span><\/p>\n<\/li>\n

    2. \n

      Calithera Biosciences <\/span><\/p>\n<\/li>\n

    3. \n

      Hoffman-La-Roche <\/span><\/p>\n<\/li>\n

    4. \n

      X4 Pharmaceuticals <\/span><\/p>\n<\/li>\n

    5. \n

      Bristol-Myers Squibb <\/span><\/p>\n<\/li>\n

    6. \n

      Novartis Pharmaceuticals <\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Advanced Renal Cell Carcinoma treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drugs covered<\/strong><\/p>\n

        \n
      1. \n

        (NKTR-214) <\/span><\/p>\n<\/li>\n

      2. \n

        (CB-839)<\/span><\/p>\n<\/li>\n

      3. \n

        (Atezolizumab)<\/span><\/p>\n<\/li>\n

      4. \n

        (X4P-001)<\/span><\/p>\n<\/li>\n

      5. \n

        (Nivolumab\/Ipilimumab)<\/span><\/p>\n<\/li>\n

      6. \n

        (Pazopanib\/Sunitinib)<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/advanced-renal-cell-carcinoma-rcc-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4.  Advanced Renal Cell Carcinoma Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5.  Advanced Renal Cell Carcinoma Market Overview at a Glance<\/span><\/p>\n

        6.  Advanced Renal Cell Carcinoma Disease Background and Overview<\/span><\/p>\n

        7.  Advanced Renal Cell Carcinoma Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of  Advanced Renal Cell Carcinoma<\/span><\/p>\n

        9.  Advanced Renal Cell Carcinoma Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11.  Advanced Renal Cell Carcinoma Emerging Therapies<\/span><\/p>\n

        12.  Advanced Renal Cell Carcinoma Market Outlook<\/span><\/p>\n

        13. Country-Wise  Advanced Renal Cell Carcinoma Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18.  Advanced Renal Cell Carcinoma Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        Advanced Renal Cell Carcinoma- Pipeline Insights, 2021<\/strong><\/p>\n

        “<\/span>Advanced Renal Cell Carcinoma Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the  Advanced Renal Cell Carcinoma market. A detailed picture of the  Advanced Renal Cell Carcinoma pipeline landscape is provided, which includes the disease overview and  Advanced Renal Cell Carcinoma treatment guidelines.<\/span><\/p>\n

        Advanced Renal Cell Carcinoma- Epidemiology Forecast 2030<\/strong><\/p>\n

        DelveInsight’s ‘<\/span> Advanced Renal Cell Carcinoma- Epidemiology Forecast to 2030<\/span>‘ report delivers an in-depth understanding of the disease, historical and forecasted  Advanced Renal Cell Carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

         <\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Advanced Renal Cell Carcinoma (RCC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Advanced Renal Cell Carcinoma (RCC) , historical and forecasted epidemiology as well as the Advanced Renal … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542609","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542609"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542609\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}